The 125 references in paper S. Avdeev N., С. Авдеев Н. (2016) “Идиопатический легочный фиброз // Idiopathic pulmonary fibrosis” / spz:neicon:pulmonology:y:2015:i:5:p:600-612

1
Raghu G., Collard H.R., Egan J.J. et al. An official ATS / ERS / JRS / ALAT statement: idiopathic pulmonary fibrosis; evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788–824.
(check this in PDF content)
2
Raghu G., Rochwerg B., Zhang Y. et al. An Official ATS / ERS / JRS / ALAT Clinical Practice Guideline: Treatment of idiopathic pulmonary fibrosis: Executive summary. An update of the 2011 Clinical Practice Guideline. Am. J. Respir. Crit. Care Med.2015; 192: e3–e19.
(check this in PDF content)
3
American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment; international consensus statement. Am. J. Respir. Crit. Care Med. 2000; 161: 646–664.
(check this in PDF content)
4
Ryu J.H., Moua T., Daniels C.E. et al. Idiopathic pulmonary fibrosis: Evolving concepts. Mayo. Clin. Proc. 2014; 89: 1130–1142.
(check this in PDF content)
5
Travis W.D., Costabe U., Hansell D.M. et al. An official American Thoracic Society / European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med.2013; 188: 733–748.
(check this in PDF content)
6
Collard H.R., King T.E. Demystifying idiopathic interstitial pneumonia. Arch. Intern. Med. 2003; 163: 17–29.
(check this in PDF content)
7
American Thoracic Society. European Respiratory Society. American Thoracic Society / European RespiratorySociety international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2002; 165: 277–304.
(check this in PDF content)
8
Katzenstein A.L., Myers J.L. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. J. Respir. Crit. Care Med.1998; 157: 1301–1315.
(check this in PDF content)
9
Richeldi L., Sperb Rubin A., Avdeev S. et al. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Medicine. 2015; 13: 237.
(check this in PDF content)
10
Rindfleisch G.E. Ueber cirrhosis cystica pulmonum. Zentralbl. Pathol.1897; 8: 864–865.
(check this in PDF content)
11
Илькович М.М., Новикова Л.Н., Королева М.Г. Идиопатический фиброзирующий альвеолит: противоречия в современных представлениях. Пульмонология. 2003; 3: 98–101. / Il'kovich M.M., Novikova L.N., Koroleva M.G. Idiopathic pulmonary fibrosis: controversies in the current view. Pul'monologiya. 2003; 3: 98–101 (in Russian).
(check this in PDF content)
12
Илькович М.М., Новикова Л.Н., Сперанская А.А. Идиопатический фиброзирующий альвеолит: современные представления. Consilium Medicum. 2009; 11: 24–29. / Il'kovich M.M., Novikova L.N., Speranskaya A.A.Idiopathic pulmonary fibrosis: the current view. Consilium Medicum. 2009; 11: 24–29 (in Russian)
(check this in PDF content)
13
Bjoraker J.A., Ryu J.H., Edwin M.K. et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.1998; 157: 199–203.
(check this in PDF content)
14
Nagai S., Kitaichi M., Itoh H. et al. Idiopathic nonspecific interstitial pneumonia / fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP. Eur. Respir. J.1998; 12: 1010–1019.
(check this in PDF content)
15
Daniil Z.D., Gilchrist F.C., Nicholson A.G. et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care Med.1999; 160: 899–905.
(check this in PDF content)
16
Fernández Pérez E.R., Daniels C.E., Schroeder D.R. et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest. 2010; 137: 129–137. Авдеев С.Н.Идиопатический легочный фиброз
(check this in PDF content)
17
Raghu G., Weycker D., Edelsberg J. et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2006; 174: 810–816.
(check this in PDF content)
18
Douglas W.W., Ryu J.H., Schroeder D.R. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival.Am. J. Respir. Crit. Care Med.2000; 161: 1172–1178.
(check this in PDF content)
19
King T.E., Tooze J.A., Schwarz M.I. et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am. J. Respir. Crit. Care Med.2001; 164: 1171–1181.
(check this in PDF content)
20
Nadrous H.F., Myers J.L., Decker P.A., Ryu J.H. Idiopathic pulmonary fibrosis in patients younger than 50 years.Mayo. Clin. Proc. 2005; 80: 37–40.
(check this in PDF content)
21
Selman M., King T.E., Pardo A. American Thoracic Society; European Respiratory Society; American College of Chest Physicians. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med.2001; 134: 136–151.
(check this in PDF content)
22
du Bois R.M. Strategies for treating idiopathic pulmonary fibrosis. Nat. Rev. Drug. Discov.2010; 9: 129–140.
(check this in PDF content)
23
Allam J.S., Limper A.H. Idiopathic pulmonary fibrosis: is it a familial disease? Curr. Opin. Pulm. Med. 2006; 12: 312–317.
(check this in PDF content)
24
Steele M.P., Speer M.C., Loyd J.E. et al. Clinical and pathologic features of familial interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2005; 172: 1146–1152.
(check this in PDF content)
25
Lee H.-L., Ryu J.H., Wittmer M.H. et al. Familial idiopathic pulmonary fibrosis: clinical features and outcome. Chest. 2005; 127: 2034–2041.
(check this in PDF content)
26
Wahidi M.M., Speer M.C., Steele M.P. et al. Familial pulmonary fibrosis in the United States. Chest. 2002; 121: 30.
(check this in PDF content)
27
Taskar V., Coultas D. Exposures and idiopathic lung disease. Semin. Respir. Crit. Care Med.2008; 29: 670–679.
(check this in PDF content)
28
Blackwell T.S., Tager A.M., Borok Z. et al. Future directions in idiopathic pulmonary fibrosis research: an NHLBI workshop report.Am. J. Respir. Crit. Care Med.2014; 189: 214–222.
(check this in PDF content)
29
Rosas I.O., Kottman R.M., Sime P.J. New light is shed on the enigmatic origin of the lung myofibroblast. Am. J. Respir. Crit. Care Med. 2013; 188: 765–766.
(check this in PDF content)
30
Phan S.H. Genesis of the myofibroblast in lung injury and fibrosis. Proc. Am. Thorac. Soc. 2012; 9: 148–152.
(check this in PDF content)
31
Xia H., Bodempudi V., Benyumov A. et al. Identification of a cell-of-origin for fibroblasts comprising the fibrotic reticulum in idiopathic pulmonary fibrosis Am. J. Pathol.2014; 184: 1369–1383.
(check this in PDF content)
32
Noble P.W., Barkauskas C.E., Jiang D. Pulmonary fibrosis: patterns and perpetrators.J. Clin. Invest.2012; 122: 2756–2762.
(check this in PDF content)
33
Maher T.M. Beyond the diagnosis of idiopathic pulmonary fibrosis: the growing role of systems biology and stratified medicine. Curr. Opin. Pulm. Med.2013; 19: 460–465.
(check this in PDF content)
34
Shimbori C., Gauldie J., Kolb M. Extracellular matrix microenvironment contributes actively to pulmonary fibrosis. Curr. Opin. Pulm. Med.2013; 19: 446–452.
(check this in PDF content)
35
Alder J.K., Chen J.J., Lancaster L. et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc. Natl. Acad. Sci.2008; 105: 13051–13056.
(check this in PDF content)
36
Chilosi M., Carloni A., Rossi A., Poletti V. Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD / emphysema. Transl. Res. 2013; 162: 156–173.
(check this in PDF content)
37
Leslie K.O. Idiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the aging lung: a unifying hypothesis regarding etiology and pathogenesis.Arch. Pathol. Lab. Med.2012; 136: 591–600.
(check this in PDF content)
38
Seibold M.A., Wise A.L., Speer M.C. et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N. Engl. J. Med. 2011; 364: 1503–1512.
(check this in PDF content)
39
Peljto A.L., Zhang Y., Fingerlin T.E. et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013; 309: 2232–2239.
(check this in PDF content)
40
Armanios M.Y., Chen J.J., Cogan J.D. et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2007; 356: 1317–1326.
(check this in PDF content)
41
Cronkhite J.T., Xing C., Raghu G. et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.2008; 178: 729–737.
(check this in PDF content)
42
Liu T., Ullenbruch M., Young Choi Y. et al. Telomerase and telomere length in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol.2013; 49: 260–268.
(check this in PDF content)
43
Thomas A.Q., Lane K., Phillips J. et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred.Am. J. Respir. Crit. Care Med. 2002; 165: 1322–1328.
(check this in PDF content)
44
Wang Y., Kuan P.J., Xing C. et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am. J. Hum. Genet. 2009; 84: 52–59.
(check this in PDF content)
45
Behr J., Ryu J.H. Pulmonary hypertension in interstitial lung disease. Eur. Respir. J. 2008; 31: 1357–1367.
(check this in PDF content)
46
Nathan S.D., Noble P.W., Tuder R.M. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am. J. Respir. Crit. Care Med.2007; 175: 875–880.
(check this in PDF content)
47
Zhang Y., Kaminski N. Biomarkers in idiopathic pulmonary fibrosis. Curr. Opin. Pulm. Med.2012; 18: 441–446.
(check this in PDF content)
48
Vij R., Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl. Res. 2012; 159: 218–227.
(check this in PDF content)
49
Tzouvelekis A., Kouliatsis G., Anevlavis S., Bouros D. Serum biomarkers in interstitial lung diseases. Respir. Res. 2005; 6: 78.
(check this in PDF content)
50
Prasse A., Müller-Quernheim J. Non-invasive biomarkers in pulmonary fibrosis. Respirology. 2009; 14: 788–795.
(check this in PDF content)
51
Авдеева О.Е., Лебедин Ю.С., Авдеев С.Н. и др. Гликозилированный муцин-антиген 3EG5 – сывороточный маркер активности и тяжести при интерстициальных заболеваниях легких. Пульмонология. 1998; 2: 22–27. / Avdeeva O.E., Lebedin Yu.S., Avdeev S.N. et al. 3EG5 glycosilazed mucin antigen is a serum biomarker of activity and severity of interstitial lung disease. Pul'monologiya. 1998; 2: 22–27 (in Russian).
(check this in PDF content)
52
Silva C.I., Müller N.L. Idiopathic interstitial pneumonias. J. Thorac. Imaging.2009; 24: 260–273.
(check this in PDF content)
53
Lynch D.A., Godwin J.D., Safrin S. et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am. J. Respir. Crit. Care Med.2005; 172: 488–493.
(check this in PDF content)
54
Arakawa H., Honma K. Honeycomb lung: history and current concepts. Am. J. Roentgenol. 2011; 196: 773–782.
(check this in PDF content)
55
Martinez F.J., Flaherty K. Pulmonary function testing in idiopathic interstitial pneumonias. Proc. Am. Thorac. Soc. 2006; 3: 315–321.
(check this in PDF content)
56
Cottin V., Nunes H., Brillet P.Y. et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur. Respir. J.2005; 26: 586–593.
(check this in PDF content)
57
Jankowich M.D., Rounds S.I. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest. 2012; 141: 222–231. Обзоры
(check this in PDF content)
58
Ryerson C.J., Hartman T., Elicker B.M. et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013; 144: 234–240.
(check this in PDF content)
59
Trahan S., Hanak V., Ryu J.H., Myers J.L. Role of surgical lung biopsy in separating chronic hypersensitivity pneumonia from usual interstitial pneumonia / idiopathic pulmonary fibrosis: analysis of 31 biopsies from 15 patients. Chest. 2008; 134: 126–132.
(check this in PDF content)
60
Misumi S., Lynch D.A. Idiopathic pulmonary fibrosis / usual interstitial pneumonia: imaging diagnosis, spectrum of abnormalities, and temporal progression. Proc. Am. Thorac. Soc. 2006; 3: 307–314.
(check this in PDF content)
61
Ryu J.H., Daniels C.E., Hartman T.E., Yi E.S. Diagnosis of interstitial lung diseases.Mayo. Clin. Proc.2007; 82: 976–986.
(check this in PDF content)
62
Leslie K.O., Gruden J.F., Parish J.M., Scholand M.B. Transbronchial biopsy interpretation in the patient with diffuse parenchymal lung disease.Arch. Pathol. Lab. Med. 2007; 131: 407–423.
(check this in PDF content)
63
Ohshimo S., Bonella F., Cui A. et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.2009; 179: 1043–1047.
(check this in PDF content)
64
Casoni G.L., Tomassetti S., Cavazza A. et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS One.2014; 9: e86716.
(check this in PDF content)
65
Maldonado F., Ryu J.H. Surgical biopsy for diffuse parenchymal lung diseases: are we causing more harm than good? J. Bronchology Interv. Pulmonol.2009; 16: 227–228.
(check this in PDF content)
66
Riley D.J., Costanzo E.J. Surgical biopsy: its appropriateness in diagnosing interstitial lung disease. Curr. Opin. Pulm. Med.2006; 12: 331–336.
(check this in PDF content)
67
Sharma S. Diagnosing idiopathic pulmonary fibrosis: to biopsy or not to biopsy [editorial]. Curr. Opin. Pulm. Med. 2012; 18: 528–529.
(check this in PDF content)
68
Utz J.P., Ryu J.H., Douglas W.W. et al. High short-term mortality following lung biopsy for usual interstitial pneumonia.Eur. Respir. J.2001; 17: 175–179.
(check this in PDF content)
69
Park J.H., Kim D.K., Kim D.S. et al. Mortality and risk factors for surgical lung biopsy in patients with idiopathic interstitial pneumonia.Eur. J. Cardiothorac. Surg.2007; 31: 1115–1119.
(check this in PDF content)
70
Flaherty K.R., King T.E., Raghu G. et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?Am. J. Respir. Crit. Care Med. 2004; 170: 904–910.
(check this in PDF content)
71
Smith M., Dalurzo M., Panse P. et al. Usual interstitial pneumonia-pattern fibrosis in surgical lung biopsies: clinical, radiological and histopathological clues to aetiology. J. Clin. Pathol. 2013; 66: 896–903.
(check this in PDF content)
72
Ley B., Collard H.R., King T.E. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 183: 431–440.
(check this in PDF content)
73
Selman M., Carrillo G., Estrada A. et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One.2007; 2: e482.
(check this in PDF content)
74
Wells A.U., Desai S.R., Rubens M.B. et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am. J. Respir. Crit. Care Med.2003; 167: 962–969.
(check this in PDF content)
75
Ley B., Ryerson C.J., Vittinghoff E. et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann. Intern. Med.2012; 156: 684–691.
(check this in PDF content)
76
du Bois R.M., Weycker D., Albera C. et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.2011; 184: 459–466.
(check this in PDF content)
77
Daniels C.E., Yi E.S., Ryu J.H. Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 2008; 32: 170–174.
(check this in PDF content)
78
Panos R.J., Mortenson R.L., Niccoli S.A., King T.E. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am. J. Med.1990; 88: 396–404.
(check this in PDF content)
79
Spagnolo P., Wells A.U., Collard H.R. Pharmacological treatment of idiopathic pulmonary fibrosis: an update. Drug Discovery Today; 2015. http://dx.doi.org/10.1016/ j.drud' is.2015.01.001
(check this in PDF content)
80
Wolters P.J., Collard H.R., Jones K.D. Pathogenesis of idiopathic pulmonary fibrosis. Ann. Rev. Pathol.2014; 9: 157–179.
(check this in PDF content)
81
Richeldi L., Davies H.R., Ferrara G. et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev.2003; 3: CD002880.
(check this in PDF content)
82
Richeldi L., Davies H.R., Spagnolo P. et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2010; 2: CD002880.
(check this in PDF content)
83
Raghu G., Anstrom K.J., King T.E. et al. Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med.2012; 366: 1968–1977.
(check this in PDF content)
84
Spagnolo P., Del Giovane C., Luppi F. et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2010; 9: CD003134.
(check this in PDF content)
85
King T.E., Pardo A., Selman M. Idiopathic pulmonary fibrosis. Lancet2011; 378: 1949–1961.
(check this in PDF content)
86
Gauldie J., Kolb M. Animal models of pulmonary fibrosis: how far from effective reality? Am. J. Physiol. Lung Cell Mol. Physiol.2008; 294: L151.
(check this in PDF content)
87
Noble P.W., Richeldi L., Kaminski N. End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.2011; 184: 4–5.
(check this in PDF content)
88
Ziesche R., Hofbauer E., Wittmann K. et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med.1999; 341: 1264–1269.
(check this in PDF content)
89
Raghu G., Brown K.K., Bradford W.Z. et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.N. Engl. J. Med.2004; 350: 125–133.
(check this in PDF content)
90
King T.E., Albera C., Bradford W.Z. et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009; 374: 222–228.
(check this in PDF content)
91
Luppi F., Losi M., D’Amico R. et al. Endogenous blood maximal interferon-gamma production may predict response to interferon-gamma 1beta treatment in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2009; 26: 64–68.
(check this in PDF content)
92
Casoni G.L., Chilosi M., Romagnoli M. et al. Another «chance» for interferon gamma-1b? Sarcoidosis Vasc. Diffuse Lung Dis.2011; 28: 79–80.
(check this in PDF content)
93
King T.E., Behr J., Brown K.K. et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2008; 177: 75–81.
(check this in PDF content)
94
King T.E., Brown K.K., Raghu G. et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.Am. J. Respir. Crit. Care Med. 2011; 184: 92–99.
(check this in PDF content)
95
Raghu G., Brown K.K., Costabel U. et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, Авдеев С.Н.Идиопатический легочный фиброз placebo-controlled trial.Am. J. Respir. Crit. Care Med.2008; 178: 948–955.
(check this in PDF content)
96
Daniels C.E., Lasky J.A., Limper A.H. et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am. J. Respir. Crit. Care Med. 2010; 181: 604–610.
(check this in PDF content)
97
Richeldi L., Brown K.K., Costabel U. et al. The oral triple kinase inhibitor BIBF 1120 reduces decline in lung function in patients with idiopathic pulmonary fibrosis (IPF): results from the tomorrow study. Am. J. Respir. Crit. Care Med. 2011; 183: A5303.
(check this in PDF content)
98
Richeldi L., Costabel U., Selman M. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med.2011; 365: 1079–1087.
(check this in PDF content)
99
Richeldi L., du Bois R.M., Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2071–2082.
(check this in PDF content)
100
Raghu G., Johnson W.C., Lockhart D. et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label phase II study.Am. J. Respir. Crit. Care Med. 1999; 159: 1061–1069.
(check this in PDF content)
101
Horita A., Nukiwa T., Tsuboi E. et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.2005; 171: 1040–1047.
(check this in PDF content)
102
Taniguchi H., Ebina M., Kondoh Y. et al. Pirfenidone in idiopathic pulmonary fibrosis.Eur. Respir. J.2010; 35: 821–829.
(check this in PDF content)
103
Noble P.W., Albera C., Bradford W.Z. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377: 1760–1769.
(check this in PDF content)
104
King T.E., Bradford W.Z., Castro-Bernardini S. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med.2014; 370: 2083–2092.
(check this in PDF content)
105
Demedts M., Behr J., Buhl R. et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis.N. Engl. J. Med.2005; 353: 2229–2242.
(check this in PDF content)
106
Martinez F.J., de Andrade J.A., Anstrom K.J. et al. Randomized trial of N-cetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2093–2101.
(check this in PDF content)
107
Kubo H., Nakayama K., Yanai M. et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest. 2005; 128: 1475–1482.
(check this in PDF content)
108
Noth I., Anstrom K.J., Calvert S.B. et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.2012; 186: 88–95.
(check this in PDF content)
109
Vries J., Kessels B.L., Drent M. Quality of life of idiopathic pulmonary fibrosis patients. Eur. Respir. J.2001; 17: 954–961.
(check this in PDF content)
110
Ries A.L., Bauldoff G.S., Carlin B.W. et al. Pulmonary rehabilitation: Joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest. 2007; 131 (Suppl. 5): 4S–42S.
(check this in PDF content)
111
Douglas W.W., Ryu J.H., Schroeder D.R. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am. J. Respir. Crit. Care Med.2000; 161: 1172–1178.
(check this in PDF content)
112
Nici L., Donner C., Wouters E. et al. American Thoracic Society / European Respiratory Society statement on pulmonary rehabilitation. Am. J. Respir. Crit. Care Med. 2006; 173: 1390–1413.
(check this in PDF content)
113
Spruit M.A., Janssen D.J., Franssen F.M. et al. Rehabilitation and palliative care in lung fibrosis. Respirology. 2009; 14: 781–787.
(check this in PDF content)
114
Holland A.E., Hill C.J., Conron M. et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008; 63: 549–554.
(check this in PDF content)
115
Saydain G., Islam A., Afessa B. et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am. J. Respir. Crit. Care Med. 2002; 166: 839–842.
(check this in PDF content)
116
Stern J.B., Mal H., Groussard O. et al. Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure. Chest. 2001; 120: 213–219.
(check this in PDF content)
117
Mallick S. Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Respir. Med. 2008; 102: 1355–1359.
(check this in PDF content)
118
Beckmann A., Benk C., Beyersdorf F. et al. Position article for the use of extracorporeal life support in adult patients. Eur. J. Cardiothorac. Surg. 2011; 40: 676–680.
(check this in PDF content)
119
Allen S., Raut S., Woollard J. et al. Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis. Palliat. Med. 2005; 19: 128–130.
(check this in PDF content)
120
Ryerson C.J., Berkeley J., Carrieri-Kohlman V.L. et al. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest. 2011; 139: 609–616.
(check this in PDF content)
121
Trulock E.P., Edwards L.B., Taylor D.O. et al. The Registry of the International Society for Heart and Lung Transplantation: twentieth official adult lung and heart-lung transplant report-2003. J. Heart Lung. Transplant. 2003; 22: 625–635.
(check this in PDF content)
122
Yusen R.D., Shearon T.H., Qian Y. et al. Lung transplantation in the United States, 1999-2008. Am. J. Transplant. 2010; 10: 1047–1068.
(check this in PDF content)
123
Mason D.P., Brizzio M.E., Alster J.M. et al. Lung transplantation for idiopathic pulmonary fibrosis. Ann. Thorac. Surg.2007; 84: 1121–1128.
(check this in PDF content)
124
Keating D., Levvey B., Kotsimbos T. et al. Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years.Transplant. Proc.2009; 41: 289–291.
(check this in PDF content)
125
Algar F.J., Espinosa D., Moreno P. et al. Results of lung transplantation in idiopathic pulmonary fibrosis patients. Transplant. Proc. 2010; 42: 3211–3213. Поступила 18.11.15 УДК 616.248004
(check this in PDF content)